Short answer
AMICUS THERAPEUTICS, INC. (FOLD) filed an 8-K current report with the SEC on April 27, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement), Item 3.01 (Notice of Delisting), Item 5.02 (Departure/Election of Directors or Officers), Item 5.03 (Amendments to Articles of Incorporation or Bylaws). April 27, 2026 repayment and termination of Amicus Credit Agreement obligations in connection with the Merger.
- This filing includes Item 3.01, an item that often signal trouble.
AMICUS THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.02 · Termination of a Material Definitive Agreement
- April 27, 2026 repayment and termination of Amicus Credit Agreement obligations in connection with the Merger
- All outstanding indebtedness, amounts payable and lender commitments fully extinguished
- Guarantees and liens securing the credit facility discharged and released
- Debt termination removes associated borrowing obligations and collateral encumbrances post-Merger
Item 3.01 · Notice of Delisting
- Merger consummation transferred control of Amicus Therapeutics to Parent
- Amicus became a wholly owned subsidiary of Parent
- Transaction likely removes public-company ownership for existing shareholders
- No known arrangements for another control change
Item 5.02 · Departure/Election of Directors or Officers
- Merger closed; all nine pre-merger directors resigned and left board committees
- Resignations unrelated to disagreements, reducing governance-transition concerns
- Eric Davis and Brian Mueller became surviving corporation directors
- Former executive team ceased serving, including Bradley Campbell, Simon Harford and Ellen Rosenberg
- Davis became President and Secretary; Mueller became Treasurer, signaling full post-merger management transition
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- Certificate of incorporation amended and restated at merger closing under the Merger Agreement
- Bylaws amended and restated to conform to Merger Sub’s governance documents
- Changes formalize the post-merger Surviving Corporation’s legal and governance structure
- Amended charter and bylaws filed as Exhibits 3.1 and 3.2 for shareholder review
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AMICUS THERAPEUTICS, INC. 8-K filings
Get the next FOLD 8-K as it lands
Follow FOLD for push alerts, or ask the research agent what this filing means.